Trials / Recruiting
RecruitingNCT05391126
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Reema A. Patel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\*1/\*28) (heterozygotes) and usual UGT metabolizers (\*1/\*1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1 genotypes (\*1/\*28, \*1/\*1) will be randomized to genotype-guided dosing versus usual care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan | Usual dosing per package insert. |
Timeline
- Start date
- 2022-09-28
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2022-05-25
- Last updated
- 2025-12-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05391126. Inclusion in this directory is not an endorsement.